• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Caris Life Sciences Inc.

    6/16/26 10:46:40 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    8-A12B 1 tm2617492d1_8a12b.htm FORM 8-A12B

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-A

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Caris Life Sciences, Inc.

    (Exact name of registrant as specified in its charter)

     

    Texas 85-2077369
    (State or other jurisdiction
    of incorporation or organization)
    (IRS Employer Identification No.)

     

    750 W. John Carpenter Freeway, Suite 800  
    Irving, TX 75039
    (Address of principal executive offices) (Zip Code)

     

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class Name of each exchange on which
    to be registered each class is to be registered

     

    Common stock, $0.001 par value NYSE Texas, Inc.

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

     

    Securities Act registration statement or Regulation A offering statement file number to which this form relates: N/A

     

    Securities to be registered pursuant to Section 12(g) of the Act:

     

    None

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form 8-A (this "Form 8-A") is being filed by Caris Life Sciences, Inc. (the “Registrant”), with the Securities and Exchange Commission (the "Commission") in connection with the dual listing of its common stock, $0.001 par value per share (the “Common Stock”) with NYSE Texas, Inc. (the “NYSE Texas”) under the trading symbol "CAI." The Common Stock is currently listed on The Nasdaq Stock Market LLC under the symbol "CAI."

     

    Item 1. Description of Registrant's Securities to be Registered.

     

    The description of the Common Stock, as may be amended from time to time, contained in Exhibit 4.2, Description of Registrant’s Securities, which was originally filed with the Commission on March 3, 2026 with the Registrant’s most recent Annual Report on Form 10-K, to which this Form 8-A relates, is incorporated herein by reference. The Registrant expects the listing and trading of the Common Stock on the NYSE Texas to commence on June 17, 2026.

     

    Item 2. Exhibits.

     

    Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the NYSE Texas, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

        Caris Life Sciences, Inc.
         
    Date: June 16, 2026 By: /s/ Luke Power
        Luke Power
        Senior Vice President, Chief Financial Officer and Chief Accounting Officer

     

     

    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    6/2/2026Peer Perform
    Wolfe Research
    4/13/2026$28.00Buy
    Jefferies
    4/10/2026$21.00Neutral
    Piper Sandler
    4/1/2026$27.00Buy
    Goldman
    2/17/2026$26.00Outperform
    Robert W. Baird
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    More analyst ratings

    $CAI
    SEC Filings

    View All

    SEC Form CERT filed by Caris Life Sciences Inc.

    CERT - Caris Life Sciences, Inc. (0002019410) (Filer)

    6/16/26 11:09:32 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 8-A12B filed by Caris Life Sciences Inc.

    8-A12B - Caris Life Sciences, Inc. (0002019410) (Filer)

    6/16/26 10:46:40 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    6/5/26 5:03:34 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Announces Dual Listing on NYSE Texas

    IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market."Establishing a dual listing on NYSE Texas re

    6/16/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Announces Share Repurchase Program

    IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as ame

    6/8/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

    Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-nega

    5/26/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Vacirca Jeff L bought $501,426 worth of shares (31,050 units at $16.15), increasing direct ownership by 167% to 49,671 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    5/12/26 8:22:31 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/2/26 5:44:17 PM ET
    $CAI
    Medical Specialities
    Health Care

    Director Knowles Jonathan Kenneth Charles was granted 1,600 shares, increasing direct ownership by 0.52% to 308,979 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/2/26 5:43:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel covered exercise/tax liability with 6,047 shares, decreasing direct ownership by 3% to 181,515 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    5/18/26 4:23:48 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Caris Life Sciences

    Wolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform

    6/2/26 8:32:11 AM ET
    $CAI
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Caris Life Sciences with a new price target

    Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00

    4/13/26 8:51:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on Caris Life Sciences with a new price target

    Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00

    4/10/26 8:31:01 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences Reports First Quarter 2026 Financial Results

    Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres

    5/7/26 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care